Lv4
450 积分 2022-03-09 加入
[Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version)]
1天前
已完结
[Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib]
1天前
已完结
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
9个月前
已完结
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
9个月前
已完结
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
1年前
已关闭
[Evaluation considerations for using surrogate endpoints in anticancer clinical trials]
1年前
已完结
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer
1年前
已完结
Interferon-dependent SLC14A1 cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer
1年前
已完结
Interferon-dependent SLC14A1 cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer
1年前
已完结
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
1年前
已完结
皖公网安备34019202002308
